Pen me down
Endocrinology
Cardiology
Miscellaneous
ID or not
100

This trial showed that in patients with HFpEF and obesity but no DM, semaglutide significantly improved heart failure–related symptoms and physical limitations, increased exercise capacity, and led to substantial weight loss over 52 weeks compared to placebo

STEP-HFpEF

100

This selective estrogen modulator is used to treat the genitourinary syndrome of menopause

Ospemifene

100

This new equation is used to predict ASCVD and incidnet CKD events in at risk individuals

PREVENT equation

100

This decompression sickness is seen in deep sea divers

Caissons diease

100

This oral antiviral combination is first line for outpatient treatment in COVID-19

Nirmatrelvir-Ritonavir (Paxlovid)

200

This trial showed that semaglutide improved cardiovascular outcomes in obesity without diabetes

SELECT trial

200

This once weekly basal insulin bound to albumin maintained glycemic control comparable to daily glargine

Insulin Icodec

200

This non steroidal MRA reduced heart failure events and hospitalizations.

Finerenone

200

This trial comparing chlorthalidone, lisinopril, amlodipine and doxazosin had significant implications for clinical practice, leading to recommendations for the use of thiazide diuretics as the first-line treatment for hypertension

ALLHAT trial

200

Double Jeopardy:

This medication is the first oral Treatment for postpartum depression

Zuranolone


300

This Oral GLP-1 agonist achieved glucose control and weight loss comparable to injectable GLP-1 agonists in the ATTAIN-1 trial

Orforglipron

300

Fixed dose of this GLP-1 agonist and amylin combination produces marked weight loss reduction

CagriSema, cagrilintide and semaglutide

REDEFINE 2 trial

300

This dual SGLT1&2 inhibitor lowered HF events and glycemia in diabetics

Sotagliflozin- SOLOIST- WHF trial

300

This small interfering RNA (siRNA) inhibits proprotein convertase preventing PCSK9 translation and is used for the treatment of high LDL, (ASCVD), and heterozygous familial hypercholesterolemia (HeFH).

Inclisiran/Leqvio

300

Father of Genetics

Gregor Mendel

400

This GLP-1 agoist is FDA approved for the treatment of OSA

Tirzepatide

400

This is a fully human recombinant IgG4 monoclonal antibody that inhibits angiopoietin-like protein 3 (ANGPTL3) used to treat homozygous familial hypercholesterolemia.

Evinacumab/ Evkeeza

400

This ATP-citrate lyase inhibitor is used when statins are not tolerated

Bempedoic acid

- CLEAR outcomes trial

400

This endothelin and angiotensin II receptor antagonist is used to treat IgA nephropathy

Sparsentan/ Filspari

400

This novel oral DNA gyrase inhibitor was non -inferior to nitrofurantoin in UTI

Gepotidacin

500

In patients with pulmonary arterial hypertension who were receiving stable background therapy, this medication resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo

Sotatercept as shown in the STELLAR trial

500

Name for inhaled ultra rapid acting human insulin

Afrezza

500

This new transthyretin stabilizer is used in the treatment of cardiac amyloidosis and was FDA approved in November 2024

Acoramidis/ Attruby

500

This dual PDE 3/4 inhibitor which is delivered by nebulizer reduces COPD exacerbations and improves FEV1

Ohtuvayre/ Ensifentrine

500

This twice-yearly capsid inhibitor prevented HIV acquisition with almost 100% efficacy in at risk individuals

Lenacapavir

M
e
n
u